Literature DB >> 1633356

Development of rheumatoid arthritis after chronic hepatitis caused by hepatitis C virus infection.

S Hirohata1, T Inoue, K Ito.   

Abstract

We describe a patient with rheumatoid arthritis (RA) who had preceding evidence of post-transfusion, non-A, non-B hepatitis. The patient showed positive serological tests for anti-hepatitis C virus (HCV) antibody. The manifestations of RA, including progressive polyarthritis and positive serum rheumatoid factors, emerged after the ameriolation of hepatitis and persisted for more than 3 years, indicating that the polyarthritis in this patient was not the prodrome of the hepatitis. This patient had HLA-DR4 and HLA-Bw54 which are found to be strongly associated with RA in Japan. It is therefore suggested that HCV may trigger the development of RA especially in genetically susceptible individuals.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1633356     DOI: 10.2169/internalmedicine.31.493

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  4 in total

1.  Immunological evaluation in oral lichen planus with chronic hepatitis C.

Authors:  Y Nagao; M Sata; K Abe; K Tanikawa; T Kameyama
Journal:  J Gastroenterol       Date:  1997-06       Impact factor: 7.527

2.  Effectiveness of glycyrrhizin for oral lichen planus in patients with chronic HCV infection.

Authors:  Y Da Nagao; M Sata; H Suzuki; K Tanikawa; K Itoh; T Kameyama
Journal:  J Gastroenterol       Date:  1996-10       Impact factor: 7.527

Review 3.  Gastrointestinal and hepatic manifestations of rheumatoid arthritis.

Authors:  Ellen C Ebert; Klaus D Hagspiel
Journal:  Dig Dis Sci       Date:  2011-01-04       Impact factor: 3.487

4.  Multiplex cytokine profiling of initial therapeutic response in patients with chronic hepatitis C virus infection.

Authors:  Harlan Wright; Philip Alex; Thuan Nguyen; Teddy Bader; Ahmet Gurakar; Anthony Sebastian; Liberty Gonzales; Gemma Wallis; Mark Naylor; Igor Dozmorov; Michael Centola; Bakr Nour
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.